Unlocking the master checkpoint of cancer immunity

Our knowledge of cancer is growing daily, bringing with it new treatment strategies. As mentioned previously (here) novel immunotherapies are at the forefront of cancer research. The immune activating monoclonal…

January 28, 2022
No Comments
Three questions to Romana Gugenberger, Chief Medical and Scientific Officer

1.   Despite novel immune-therapies against cancer there are still non-responders and relapses. Why is that? Romana Gugenberger:  Tumors are heterogeneous. Additionally, tumors are not static but evolve. Once a response…

January 28, 2022
No Comments
Press release: invIOs goes live

invIOs goes live with unique cell therapy platform and clinical-stage immuno-oncology pipeline Vienna, Austria, 16 December 2021: invIOs (innovative Immuno-Oncology) GmbH, a privately held biotechnology company developing novel therapies for…

December 15, 2021
No Comments
The immune system’s fight against cancer

Cancer is the second leading cause of death worldwide. Obviously, the complex cancer biology and simultaneous failure of our body to halt the transformation of a normal cell into cancer…

December 15, 2021
No Comments
Perspectives: The Cancer Revolution

Despite recent advances in the treatment of cancer, the disease remains a leading cause of death by disease worldwide1. It is reported that one in two people will be diagnosed…

December 14, 2021
No Comments